Nonmyeloablative alternative donor ...
Document type :
Article dans une revue scientifique: Article original
DOI :
PMID :
Permalink :
Title :
Nonmyeloablative alternative donor transplantation for hodgkin and non-hodgkin lymphoma: from the lwp-ebmt, eurocord, and cibmtr
Author(s) :
Fatobene, Giancarlo [Auteur]
Rocha, Vanderson [Auteur]
St Martin, Andrew [Auteur]
Hamadani, Mehdi [Auteur]
Robinson, Stephen [Auteur]
Bashey, Asad [Auteur]
Boumendil, Ariane [Auteur]
Brunstein, Claudio [Auteur]
Castagna, Luca [Auteur]
Dominietto, Alida [Auteur]
Finel, Herve [Auteur]
Chalandon, Yves [Auteur]
Kenzey, Chantal [Auteur]
Kharfan-Dabaja, Mohamed A. [Auteur]
Wallet, Helene [Auteur]
Moraleda, Jose M. [Auteur]
Pastano, Rocco [Auteur]
Perales, Miguel-Angel [Auteur]
El Ayoubi, Hanadi Rafii [Auteur]
Ruggeri, Annalisa [Auteur]
Sureda, Anna [Auteur]
Volt, Fernanda [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Zhang, Mei-Jie [Auteur]
Gluckman, Eliane [Auteur]
Montoto, Silvia [Auteur]
Eapen, Mary [Auteur]
Rocha, Vanderson [Auteur]
St Martin, Andrew [Auteur]
Hamadani, Mehdi [Auteur]
Robinson, Stephen [Auteur]
Bashey, Asad [Auteur]
Boumendil, Ariane [Auteur]
Brunstein, Claudio [Auteur]
Castagna, Luca [Auteur]
Dominietto, Alida [Auteur]
Finel, Herve [Auteur]
Chalandon, Yves [Auteur]
Kenzey, Chantal [Auteur]
Kharfan-Dabaja, Mohamed A. [Auteur]
Wallet, Helene [Auteur]
Moraleda, Jose M. [Auteur]
Pastano, Rocco [Auteur]
Perales, Miguel-Angel [Auteur]
El Ayoubi, Hanadi Rafii [Auteur]
Ruggeri, Annalisa [Auteur]
Sureda, Anna [Auteur]
Volt, Fernanda [Auteur]
Yakoub-Agha, Ibrahim [Auteur]

Zhang, Mei-Jie [Auteur]
Gluckman, Eliane [Auteur]
Montoto, Silvia [Auteur]
Eapen, Mary [Auteur]
Journal title :
Journal of clinical oncology . official journal of the American Society of Clinical Oncology
Abbreviated title :
J. Clin. Oncol.
Pages :
JCO1902408
Publication date :
2020-02-07
ISSN :
1527-7755
HAL domain(s) :
Sciences du Vivant [q-bio]
English abstract : [en]
To compare the outcomes of patients with Hodgkin or non-Hodgkin lymphoma undergoing nonmyeloablative haploidentical or unrelated cord blood (UCB) hematopoietic cell transplantation.
We retrospectively studied 740 patients ...
Show more >To compare the outcomes of patients with Hodgkin or non-Hodgkin lymphoma undergoing nonmyeloablative haploidentical or unrelated cord blood (UCB) hematopoietic cell transplantation. We retrospectively studied 740 patients with Hodgkin lymphoma (n = 283, 38%) and non-Hodgkin lymphoma (n = 457, 62%) age 18-75 years who received transplantations from 2009 to 2016. Data were reported to the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation, Eurocord, or Center for International Blood and Marrow Transplant Research. Of the 526 patients who received haploidentical transplantation, 68% received bone marrow and 32% received peripheral blood. All patients received a uniform transplantation conditioning regimen (2 Gy of total-body irradiation, cyclophosphamide, and fludarabine) and graft-versus-host disease prophylaxis (calcineurin inhibitor and mycophenolate). In addition, patients who received a haploidentical transplantation received posttransplantation cyclophosphamide. Compared with haploidentical bone marrow and peripheral-blood transplantations and adjusted for age, lymphoma subtype, and disease status, survival was lower after UCB transplantation (hazard ratio [HR], 1.55; PPPPPP When considering HLA-mismatched transplantation for Hodgkin or non-Hodgkin lymphoma, the data support haploidentical related donor transplantation over UCB transplantation.Show less >
Show more >To compare the outcomes of patients with Hodgkin or non-Hodgkin lymphoma undergoing nonmyeloablative haploidentical or unrelated cord blood (UCB) hematopoietic cell transplantation. We retrospectively studied 740 patients with Hodgkin lymphoma (n = 283, 38%) and non-Hodgkin lymphoma (n = 457, 62%) age 18-75 years who received transplantations from 2009 to 2016. Data were reported to the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation, Eurocord, or Center for International Blood and Marrow Transplant Research. Of the 526 patients who received haploidentical transplantation, 68% received bone marrow and 32% received peripheral blood. All patients received a uniform transplantation conditioning regimen (2 Gy of total-body irradiation, cyclophosphamide, and fludarabine) and graft-versus-host disease prophylaxis (calcineurin inhibitor and mycophenolate). In addition, patients who received a haploidentical transplantation received posttransplantation cyclophosphamide. Compared with haploidentical bone marrow and peripheral-blood transplantations and adjusted for age, lymphoma subtype, and disease status, survival was lower after UCB transplantation (hazard ratio [HR], 1.55; PPPPPP When considering HLA-mismatched transplantation for Hodgkin or non-Hodgkin lymphoma, the data support haploidentical related donor transplantation over UCB transplantation.Show less >
Language :
Anglais
Audience :
Internationale
Popular science :
Non
Administrative institution(s) :
CHU Lille
Inserm
Université de Lille
Inserm
Université de Lille
Submission date :
2021-07-06T12:45:16Z